Patent 7754481 was granted and assigned to Boehringer Ingelheim on July, 2010 by the United States Patent and Trademark Office.
The invention relates to new keratinocytes which may be cultured in vitro and the advantageous use thereof for preparing a product which can be used to treat acute and chronic wounds.